Clinical trials: Systemic Infection
Septic Shock, Sepsis
A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)
This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.
- Conditions
- Septic Shock, Sepsis, Hypovolemia
- Trial name
- VBI-S-02 (NCT06072430)
- Testing
- VBI-S
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Vivacelle Bio
Severe Sepsis
Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)
In this trial, patients with severe sepsis and low protein C levels will receive drotrecogin alfa (activated) at the normal, approved dose and time of administration [24 microgram/kilogram/hour (mcg/kg/hour) for 96 hours] or will…
- Trial name
- NCT00386425
- Testing
- Drotrecogin alfa (activated)
- Where
- 47 sites in United States, Belgium and 7 more
- Volunteers
- 486 people
- Sponsor
- Eli Lilly and Company
Candidiasis
The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis
Anidulafungin is a medicine being developed for treatment of patients with certain kinds of fungal infections. These infections due to yeast (a type of fungus) in the mouth/esophagus, in the blood or in other areas within the…
- Trial name
- NCT00056368
- Testing
- Anidulafungin, Fluconazole
- Where
- United States
- Volunteers
- 256 people
- Sponsor
- Pfizer
Sepsis, Septic Shock
Leukocyte MOrphology and CORticosteroids Response in SEPtic Patients (MOCORSEP)
Non-interventional, prospective, monocentric study on the exploration of leukocyte morphological parameters according to the infectious condition and response to corticosteroid therapy of septic patients.
- Conditions
- Sepsis, Septic Shock, Sepsis Syndrome, Infection
- Trial name
- MOCORSEP (NCT04292431)
- Where
- France
- Volunteers
- 175 people
- Sponsor
- Beckman Coulter, Inc.
COVID-19
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
A Double-blind, Randomized, Controlled, Phase 2a Study to Evaluate the Safety and Tolerability of a Newcastle Disease Virus-based Mucosal Vaccine (NDV-HXP-S-KP.2) Relative to an Approved Systemic mRNA Vaccine in Previously…
- Trial name
- NCT07215520
- Testing
- NDV-HXP-S-KP.2, COVID-19 mRNA Vaccine
- Where
- 2 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- CastleVax Inc.
Diabetes Mellitus, Type 1
Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients
The aim of this Phase I/IIa study is to identify a safe and tolerable dosage regimen of intravenously administered otelixizumab.
- Trial name
- NCT02000817
- Testing
- Otelixizumab
- Where
- 6 sites in Belgium
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Acute Kidney Injury
A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI
The purpose of this study is to determine whether recombinant Alkaline Phosphatase (recAP) is effective and save, and to determine the most effective dose, in the treatment of patients with acute kidney injury caused by sepsis.
- Trial name
- STOP-AKI (NCT02182440)
- Testing
- recAP
- Where
- 58 sites in United States, Austria and 9 more
- Volunteers
- 301 people
- Sponsor
- AM-Pharma
Sepsis
Integration of Wearable Sensor Devices Into a Single System to Predict the Onset of Sepsis
The purpose of this clinical investigation is to evaluate the integration of data from the CPC12S telemonitoring device, the CPC temperature/humidity sensor, and the IDRO sweat lactate sensor into a single system for the…
- Trial name
- IRHIS (NCT07595848)
- Testing
- CPC12S Telemonitoring System with Temperature/Humidity Sensor, IDRO Sweat Lactate Sensor
- Volunteers
- 360 people
- Sponsor
- Check Point R & D Ltd
Adult Patients at High Risk of Sepsis
Serial Measurement of Pancreatic Stone Protein (PSP) for Sepsis Early Detection in ICU Patients
In this study, 250 patients with high-risk of sepsis will be enrolled, including ≥ 50 subjects with confirmed sepsis. Diagnostic criteria for sepsis should meet the Third International Consensus Definitions for Sepsis and Septic…
- Trial name
- NCT07232784
- Testing
- blood sampling
- Where
- 3 sites in China
- Volunteers
- 250 people
- Sponsor
- Fapon Biotech Inc.
Bacteremia, Gram-Positive Bacterial Infections
Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections
This study will treat hemodialysis patients who have a central catheter that is thought to be infected with a specific bacteria (Gram positive bacteria).
- Trial name
- NCT00108433
- Testing
- Cefazolin IV, Linezolid IV, Vancomycin (IV)
- Where
- 17 sites in United States, Colombia and 5 more
- Volunteers
- 61 people
- Sponsor
- Pfizer
Septic Shock
Advanced Mesenchymal Enhanced Cell THerapY for SepTic Patients
Bacterial sepsis occurs in patients with severe infections. The condition is caused by toxic substances (toxins) released from bacteria and the patient's elevated inflammatory response to those toxins.
- Trial name
- AMETHYST (NCT04961658)
- Testing
- GEM00220
- Where
- 4 sites in Canada
- Volunteers
- 11 people
- Sponsor
- Northern Therapeutics
Severe Sepsis
S.A.F.E.BT System Extracorporeal Treatment With DIAPACT CRRT
The purpose of this study is to determine if Selective Adsorption System for Removal of Bacterial Toxins (S.A.F.E.BT) therapy is effective in the treatment of severe sepsis.
- Trial name
- SAFEbt (NCT01312675)
- Testing
- S.A.F.E.BT
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- B. Braun Medical Inc.
Sepsis, Septic Shock
Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock
The study will evaluate the vasopressor requirement, hemodynamic response and measures of tissue perfusion in patients with septic shock receiving an infusion of drotrecogin alfa (activated) compared to patients not receiving…
- Trial name
- NCT00279214
- Testing
- drotrecogin alfa (activated)
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- Eli Lilly and Company
Candida Systemic, Candida Albicans Infection
Clinical Study to Evaluate the Efficacy of an Anti-Fungal Supplement
This is a virtual, double-blind, two-arm, randomized, placebo-controlled clinical trial that will last 12 weeks. Participants will take the CanXida Remove Candida Cleansing Formula RMV or a placebo product daily and complete…
- Conditions
- Candida Systemic, Candida Albicans Infection, Candida Infection
- Trial name
- NCT06146504
- Testing
- CanXida Remove (Formula RMV)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- CanXida
Drug Safety
Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29
The novel humanized monoclonal antibody CaCP29 was developed to control the inflammatory response to various stimuli in humans and espacially during sepsis.
- Trial name
- NCT01319903
- Testing
- CaCP29, a humanized monoclonal antibody
- Where
- Germany
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- InflaRx GmbH
Sepsis, Severe Sepsis
The Utility of Ischemia Modified Albumin (IMA) in Sepsis
The purpose of this study is to determine if levels of ischemia modified albumin (IMA) in blood are elevated in patients with suspected infection and are predictive of severity of illness in patients with sepsis.
- Conditions
- Sepsis, Severe Sepsis, Systemic Inflammatory Response Syndrome, Sepsis Syndrome
- Trial name
- NCT00448968
- Where
- 3 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Inverness Medical Innovations
Sepsis, Adult Disease
Sepsis Post Market Observational Study and Potential Reduction of Time to Antibiotics - Washington University
The purpose of this study is to demonstrate that addition of the Monocyte Width Distribution (MDW) parameter to current standard of care improves a clinician's ability to recognize sepsis in the Emergency Department, resulting in…
- Conditions
- Sepsis, Adult Disease, Severe Sepsis, Emergency Department
- Trial name
- NCT04353388
- Testing
- CBC-DIFF Monocyte Volume Width Distribution (MDW)
- Where
- United States
- Volunteers
- 1,139 people
- Sponsor
- Beckman Coulter, Inc.
Sepsis, Severe Sepsis
Machine Learning Sepsis Alert Notification Using Clinical Data
Machine learning is a powerful method to create clinical decision support (CDS) tools, when training labels reflect the desired alert behavior.
- Conditions
- Sepsis, Severe Sepsis, Septic Shock
- Trial name
- HindSight P2 (NCT04005001)
- Testing
- HindSight, InSight
- Where
- 3 sites in United States
- Volunteers
- 37,986 people, healthy volunteers welcome
- Sponsor
- Dascena
Candidiasis, Candidemia
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
The purpose of the study is to determine the safety and effectiveness of two dose levels of micafungin versus caspofungin in the treatment of proven invasive candidiasis or candidemia.
- Trial name
- NCT00105144
- Testing
- Micafungin, Caspofungin
- Where
- 167 sites in United States, Austria and 13 more
- Volunteers
- 611 people
- Sponsor
- Astellas Pharma Inc
Candidiasis
Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis
The purpose of this study is to further evaluate the safety and effectiveness of intravenous anidulafungin (Eraxis™) in patients with a diagnosis of candidemia or invasive candidiasis, which is a fungus infection of the blood or…
- Trial name
- NCT00496197
- Testing
- Eraxis (anidulafungin), Diflucan (fluconazole), Vfend (voriconazole)
- Where
- 43 sites in United States, South Korea
- Volunteers
- 282 people
- Sponsor
- Pfizer